Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: A randomised, double-blind, placebo-controlled trial

The Lancet

Volumn 378, Issue 9789, 2011, Pages 412-419

  Orban, Tihamer ^a   Bundy, Brian ^b   Becker, Dorothy J ^c   DiMeglio, Linda A ^d   Gitelman, Stephen E ^e   Goland, Robin ^f   Gottlieb, Peter A ^g   Greenbaum, Carla J ^h   Marks, Jennifer B ⁱ   Monzavi, Roshanak ^j   Moran, Antoinette ^k   Raskin, Philip ^l   Rodriguez, Henry ^d   Russell, William E ^m   Schatz, Desmond ⁿ   Wherrett, Diane ^o   Wilson, Darrell M ^p   Krischer, Jeffrey P ^b   Skyler, Jay S ⁱ  

^a JOSLIN DIABETES CENTER   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d INDIANA UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h BENAROYA RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^j CHILDREN S HOSPITAL LOS ANGELES   (United States)

^k UNIVERSITY OF MINNESOTA   (United States)

^l UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^m VANDERBILT UNIVERSITY   (United States)

ⁿ UNIVERSITY OF FLORIDA   (United States)

^o HOSPITAL FOR SICK CHILDREN   (Canada)

^p STANFORD UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; C PEPTIDE; HEMOGLOBIN A1C; PLACEBO;

ADOLESCENT; ADULT; ALLERGY; ARTICLE; BONE MARROW DISEASE; CHILD; CONTROLLED STUDY; EAR DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPOGLYCEMIA; INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; LABORATORY TEST; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; VISUAL DISORDER;

EID: 79960912796     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60886-6     Document Type: Article

References (27)

1. von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nat Rev Immunol 2007; 7: 988-94. (Pubitemid 350166057)
2. Palmer JP, Fleming GA, Greenbaum CJ, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004; 53: 250-64. (Pubitemid 38044724)
3. Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial: a randomized, controlled trial. Ann Intern Med 1998; 128: 517-23.
4. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003; 26: 832-36. (Pubitemid 36929351)
5. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346: 1692-98. (Pubitemid 34547482)
6. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352: 2598-608. (Pubitemid 41007846)
7. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al, for the Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361: 2143-52.
8. Ludvigsson J, Faresjö M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359: 1909-20.
9. Marelli-Berg FM, Okkenhaug K, Mirenda V. A two-signal model for T cell trafficking. Trends Immunol 2007; 28: 267-73. (Pubitemid 46810354)
10. Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 2006; 24: 233-38.
11. Lo DJ, Weaver TA, Stempora L, et al. Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression. Am J Transplant 2011; 11: 22-33.
12. Lenschow DJ, Ho SC, Sattar H, et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995; 181: 1145-55.
13. Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103: 1243-52. (Pubitemid 29218294)
14. Mease P, Genovese MC, Gladstein G, et al. Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 2011; 63: 939-48.
15. Genant HK, Peterfy CG, Westhovens R, et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008; 67: 1084-89.
16. Ruperto N, Lovell DJ, Quartier P, et al for the Paediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008; 372: 383-91.
17. Vincenti F, Larsen C, Durrbach A. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-81. (Pubitemid 41215486)
18. American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care 2011; 33 (suppl 1): S11-61.
19. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, et al, for the Type 1 Diabetes Trial Net Research Group and European C-Peptide Trial Study Group. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008; 31: 1966-71.
20. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-63.
21. Cox DR. Regression model and life tables. J R Stat Soc Series B Stat Methodol 1972; 34: 187-220.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
23. Agresti A. Categorical data analysis. New York, NY, USA: John Wiley and Sons, 1990.
24. Luo X, Herold KC, Miller SD. Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity 2010; 32: 488-99.
25. Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010; 53: 614-23.
26. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
27. Skyler JS, Ricordi C. Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes 2011; 60: 1-8.